Abstract:Introduction: Phosphodiesterase type 5 (PDE5) inhibitors, with sildenafil the earliest among them, are widely used in the management of pediatric pulmonary arterial hypertension (PAH). Tadalafil is a PDE5 inhibitor with a long half life (16 h), stable pharmacokinetics and pharmacodynamics, and minimal adverse effects. However, the utility of tadalafil suspensions in this setting has not been widely explored due to a lack of clinical experience. We present a multicenter experience that details the safety and tolerability of a tadalafil suspension, either alone or in combination with another vasodilator, for the management of pediatric pulmonary hypertension (PH). Methods and materials: This is a retrospective chart review of infants and children at Children's Wisconsin and the Stollery Children's Hospital enrolled in pediatric PH programs between December 2013 and April 2022 managed with a tadalafil suspension. Patients aged six years of age and under who were treated with a tadalafil suspension were included. Demographics, clinical information, echocardiographic and hemodynamic measurements, and laboratory data were collected before and six months after tadalafil initiation. Results: Over the study period, 154 children with a median age of 1.0 (range 0.0-6.9) years were treated with tadalafil therapy. Of these, 39 (25.3%) were in group 1 (PAH), 79 (51.3%) were in group 3 (lung disease), and 33 (21.4%) were in group 5 (pulmonary hypertensive vascular disease). The median initial dose of tadalafil was 1.0 mg/kg once daily. Eleven (7.1%) patients in the cohort were established on tadalafil therapy de novo. The suspension formulation was necessary for 103 (66.9%) patients due to an inability to take enteral tablets and for 49 (31.8%) due to a need for feeding via gastric or jejunal tubes. We observed a statistically significant increase in tricuspid annular plane systolic excursion as well as significant decreases in right-ventricular systolic pressure and NT-proBNP. Tadalafil therapy was well tolerated over the six-month period: at six months, no adverse effects were reported aside from gastrointestinal disturbances by 2 (1.3%) patients. Conclusion: Tadalafil, a long-acting PDE5 inhibitor, when administered in a suspension formulation, has a safe and tolerable adverse effect profile. Following six months of therapy, our cohort showed improvements in clinical parameters, echocardiographic measurements, and laboratory results. Patient compliance was good and adverse effects were rare, minor, and manageable with nonpharmacological means.

Effect of Tadalafil on Heart Function in Children with Severe Pulmonary Regurgitation Following Surgical Repair of Tetralogy of Fallot: A Prospective Study

The effect of tadalafil on functional capacity and echocardiographic parameters in patients with repaired Tetralogy of Fallot

Long-term Outcome of Correction of Tetralogy of Fallot in 56 Adult Patients.

Effect of Nebulized Nitroglycerin on Children with Ventricular Septal Defect and Pulmonary Hypertension

Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension: a sub-group analysis based on Japan post-marketing surveillance

The Indispensable Role of Cardiac Catheterization Before Surgical Intervention of Pediatrics Undergoing Tetralogy of Fallot Total Correction; A Single Center Experience

Noninvasive perioperative evaluation of right ventricular function in children with tetralogy of Fallot.

Evaluation of Pulmonary Regurgitation by Using Different Cardiac Magnetic Resonance Indices in Children with Repaired Tetralogy of Fallot

Oral tadalafil in pulmonary artery hypertension: a prospective study

Sildenafil for congenital heart diseases induced pulmonary hypertension, a meta-analysis of randomized controlled trials

Long-Term Outcomes of Cardiac Resynchronization Therapy in Patients With Repaired Tetralogy of Fallot: A Multicenter Study

Tadalafil in Neonates and Infants With Pulmonary Hypertension Secondary to Bronchopulmonary Dysplasia

Comparison of tadalafil and sildenafil in controlling neonatal persistent pulmonary hypertension

C-MRI Assessment of Pulmonary Regurgitation in Repaired Tetralogy of Fallot

Correlation between pulmonary regurgitation and right ventricular function in patients with repaired tetralogy of fallot

Prevalence and optimal management strategy for aortic regurgitation in tetralogy of Fallot

Effect of Drug on Left Heart Remodeling after Transcatheter Closure of Patent Ductus Arteriosus with Domestic Occluder

Primary transcatheter dilation of the pulmonary valve in cyanotic patients with tetralogy of Fallot and dominant pulmonary valve stenosis

Electrocardiogram changes post surgical repair of tetralogy of Fallot with valve-sparing versus transannular patch: A retrospective observational study

Pulmonary Valve Replacement in Primary Repair of Tetralogy of Fallot in Adult Patients

Multicenter review of a tadalafil suspension formulation for infants and children with pulmonary hypertension: A North American experience